Version for the visually impaired:
Font size:
a
a
a

Preclinical studies of the drug on the basis of an oxime derivative as a neuroprotector in cerebrovascular diseases

  • Main
  • Preclinical studies of the drug on the basis of an oxime derivative as a neuroprotector in cerebrovascular diseases

The aim of the project was to conduct preclinical study and development of the innovative drug based on the sodium salt of 11H-indeno [1,2-b] quinoxalin-11-on-oxime (IQ-IS) as a neuroprotective agent in cerebrovascular diseases. The developed innovative drug IQ-1S is a neuroprotector with multi-targeting activity, it affects important mechanisms of neuronal damage during ischemia / reperfusion. The action of IQ-1S includes inhibition of c-Jun N-terminal kinase in brain tissue, antioxidant, hemorheological and NO-donating activity.  IQ-1S is superior in neuroprotective activity toward the neuroprotector citicoline. All the necessary preclinical studies were completed, the technology for the production of the substance and dosage form was developed, the documents for registration and clinical research were prepared. The use of IQ-1S will increase the effectiveness of cerebrovascular accidents therapy.